FDA/CDC

FDA approves subcutaneous trastuzumab for HER2-positive breast cancers


 

The Food and Drug Administration has approved a subcutaneous formulation of trastuzumab – trastuzumab and hyaluronidase-oysk (Herceptin Hylecta) – for the treatment of patients with HER2-overexpressing breast cancer.

FDA icon

Approval of the subcutaneous formulation is based on results from two clinical studies in HER2-positive early breast cancer – HannaH and SafeHER, the FDA said in a press release.

In the phase 3 HannaH study (NCT00950300), researchers compared neoadjuvant and adjuvant trastuzumab and hyaluronidase-oysk with intravenous trastuzumab, both in combination with chemotherapy. Trastuzumab and hyaluronidase-oysk proved noninferior to intravenous trastuzumab in this trial (Lancet Oncol. 2012 Sep;13[9]:869-78).

In the phase 3 SafeHER study (NCT01566721), the safety profile of trastuzumab and hyaluronidase-oysk was deemed consistent with the known safety profiles of intravenous trastuzumab and trastuzumab and hyaluronidase-oysk (Eur J Cancer. 2017 Sep;82:237-246).

The most common adverse reactions observed in patients receiving the subcutaneous formulation were fatigue, arthralgia, diarrhea, injection-site reaction, upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity, the FDA said.

Trastuzumab plus hyaluronidase-oysk was approved with a black box warning detailing the risk of cardiomyopathy, pulmonary toxicity, and embryo-fetal toxicity associated with the product.

The recommended dose is 600 mg/10,000 units (600 mg trastuzumab and 10,000 units hyaluronidase) administered subcutaneously over approximately 2-5 minutes once every 3 weeks.

Additional details can be found in the prescribing information.

Recommended Reading

Soy didn’t up all-cause mortality in breast cancer survivors
MDedge Hematology and Oncology
Progress in cancer research slowed by broken system
MDedge Hematology and Oncology
High postpartum breast cancer metastasis risk may persist for a decade
MDedge Hematology and Oncology
FDA approves third trastuzumab biosimilar
MDedge Hematology and Oncology
AML, myeloma risk higher for breast cancer survivors
MDedge Hematology and Oncology
Single-cell genomics drive progress toward human breast cell atlas development
MDedge Hematology and Oncology
Clinical relevance of tamoxifen pharmacogenetics in question
MDedge Hematology and Oncology
Therapy ups breast cancer survivors’ cardiac risks
MDedge Hematology and Oncology
Breast cancer recurrence lower, survival better with dose-intensified regimens
MDedge Hematology and Oncology
Durable responses to ADC sacituzumab in mTNBC
MDedge Hematology and Oncology